Biomarkers have been described as high-tech detectives that may predict who will get a disease and what the drug effects may be on patients. The value, behavior and mechanisms of biomarkers seem to differ by species, by disease, and by ease of validation among other criteria. This session will look at several types of biomarkers and will address the issues among species and in pre-clinical development as well as the importance of biomarkers and translational medicine. Case studies in Oncology and Neuroscience will be presented.
ROOM: Alexander Ballroom
MODERATOR: Michael Orsini, BMS

Personalized medicine promises to resolve many problems in drug discovery. Medicines given to heterogenous patient populations may be more effective if the more susceptible individuals are differentiated from non-responders or the hypersensitive. Several tumor subtypes can already be identified and correlated with the optimal therapeutics. This session will provide insights to how and why disease profiling and clinical trials could be done better. We will also explore how existing or new technologies are being applied to map and analyze genetic and tumor types so that treatment protocols can be optimized for the best outcomes.
ROOM: DOD Ballroom
MODERATOR: Rita Lim-Wilby, Conference Director, PlanetConnect

Personalized medicine promises to resolve many problems in drug discovery. Medicines given to heterogenous patient populations may be more effective if the more susceptible individuals are differentiated from non-responders or the hypersensitive. Several tumor subtypes can already be identified and correlated with the optimal therapeutics. This session will provide insights to how and why disease profiling and clinical trials could be done better. We will also explore how existing or new technologies are being applied to map and analyze genetic and tumor types so that treatment protocols can be optimized for the best outcomes.
ROOM: DOD Ballroom
MODERATOR: Rita Lim-Wilby, Conference Director, PlanetConnect